Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Up – What’s Next?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $21.86, but opened at $22.46. Sarepta Therapeutics shares last traded at $22.3030, with a volume of 420,362 shares trading hands.

Analyst Ratings Changes

A number of analysts have recently issued reports on SRPT shares. Leerink Partners raised their price target on shares of Sarepta Therapeutics from $12.00 to $15.00 and gave the stock a “market perform” rating in a report on Tuesday, September 9th. Piper Sandler increased their price objective on Sarepta Therapeutics from $15.00 to $16.00 and gave the stock a “neutral” rating in a research report on Thursday, October 30th. HC Wainwright restated a “sell” rating on shares of Sarepta Therapeutics in a research report on Monday, August 25th. BMO Capital Markets raised Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $50.00 price target on the stock in a research note on Monday, September 22nd. Finally, Bank of America raised their price objective on Sarepta Therapeutics from $16.00 to $18.00 and gave the stock an “underperform” rating in a research report on Wednesday, October 22nd. Nine equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and six have given a Sell rating to the stock. Based on data from MarketBeat.com, Sarepta Therapeutics has an average rating of “Hold” and a consensus target price of $33.68.

Sarepta Therapeutics Stock Up 0.1%

The company has a market capitalization of $2.33 billion, a PE ratio of -7.38 and a beta of 0.54. The company has a current ratio of 2.95, a quick ratio of 1.79 and a debt-to-equity ratio of 0.78. The business has a fifty day moving average of $20.97 and a 200 day moving average of $21.22.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.15). Sarepta Therapeutics had a negative return on equity of 4.85% and a negative net margin of 11.25%.The business had revenue of $399.36 million for the quarter, compared to analyst estimates of $331.51 million. During the same period in the prior year, the company posted $0.62 EPS. The firm’s revenue for the quarter was down 14.5% compared to the same quarter last year. Equities research analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Hedge Funds Weigh In On Sarepta Therapeutics

Several institutional investors have recently modified their holdings of SRPT. Inspire Investing LLC purchased a new stake in shares of Sarepta Therapeutics during the 1st quarter worth $967,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Sarepta Therapeutics by 54.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 463,342 shares of the biotechnology company’s stock valued at $29,570,000 after buying an additional 164,041 shares during the last quarter. Tempus Wealth Planning LLC raised its stake in Sarepta Therapeutics by 475.8% in the second quarter. Tempus Wealth Planning LLC now owns 20,658 shares of the biotechnology company’s stock valued at $353,000 after buying an additional 17,070 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in Sarepta Therapeutics by 21.8% during the 2nd quarter. Assenagon Asset Management S.A. now owns 867,939 shares of the biotechnology company’s stock worth $14,842,000 after buying an additional 155,358 shares during the last quarter. Finally, Trexquant Investment LP purchased a new stake in Sarepta Therapeutics during the 1st quarter worth about $11,997,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.